Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by FRISONI, G. B.
Right arrow Articles by MONDA, V. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FRISONI, G. B.
Right arrow Articles by MONDA, V. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 Medical Council on Alcohol

research-article

DISULFIRAM NEUROPATHY: A REVIEW (1971–1988) AND REPORT OF A CASE

GIOVANNI B. FRISONI and VIINCENZO DI MONDA

Clinica Neurologica dell'Università di Brescia Ospedale Civile, 25125 Brescia, Italy

Received 29 July 1988; accepted 2 March 1989

Neuropathy is one of the most severe side effects of disulfiram therapy. We report the case of a young man who developed a neuropathy following disulfiram administration, with a virtually complete recovery in 14 months. We then discuss 37 cases of disulfiram neuropathy reported since 1971. Evidence is given that: (1) there is no numerical sex prevalence, although the incidence of the disease in women is probably disproportionately high; (2) symptom onset latency is dose-dependent, being longer at 250 mg/day or less; (3) neurological deficits are also dose-dependent, being milder at 250 mg/day or less; (4) the two previous findings and single observations suggest that disulfiram neuropathy is a dose-dependent phenomenon; (5) recovery probably follows a course which depends primarily on the initial degree of impairment; (6) the genetic mechanism probably involves carbon disulfide and a hypothesis as to the possible biochemical mechanism is proposed; (7) chloral hydrate can bear a potentiation effect on neuropathy, and the association with disulfiram is best avoided.

Further, we give guidelines for the differentiation between alcoholic and disulfiram neuropathy, advise prescribing the drug at 250 mg daily or less, if possible, and stress the utmost importance of an early diagnosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
H. L. Valentine, K. Amarnath, V. Amarnath, and W. M. Valentine
Dietary Copper Enhances the Peripheral Myelinopathy Produced by Oral Pyrrolidine Dithiocarbamate
Toxicol. Sci., February 1, 2006; 89(2): 485 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. J. Johnson, V. Amarnath, K. Amarnath, H. Valentine, and W. M. Valentine
Characterizing the Influence of Structure and Route of Exposure on the Disposition of Dithiocarbamates Using Toluene-3,4-dithiol Analysis of Blood and Urinary Carbon Disulfide Metabolites
Toxicol. Sci., November 1, 2003; 76(1): 65 - 74.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.